Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fexofenadine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 6/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | DRD3 | P35462 | 3/20 | 1.00 |
| ▸ | HTR2A | P28223 | 2/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | CNR1 | P21554 | 1/20 | 1.00 |
| ▸ | APEX1 | P27695 | 1/20 | 1.00 |
| ▸ | PDE4A | P27815 | 1/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 2/20 | 0.98 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.98 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.98 |
| ▸ | CYP2J2 | P51589 | 3/20 | 0.80 |
| ▸ | MEN1 | O00255 | 1/20 | 0.80 |
| ▸ | NPC1 | O15118 | 1/20 | 0.80 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.80 |
| ▸ | GMNN | O75496 | 1/20 | 0.80 |
| ▸ | USP2 | O75604 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fexofenadine SCHEMBL4901 | 1.00 | HRH1 (1.00) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL7104316 | 1.00 | HRH1 (1.00) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL4900 | 1.00 | HRH1 (1.00) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL1561082 | 1.00 | HRH1 (1.00) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL3178320 | 1.00 | HRH1 (1.00) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL9943444 | 0.99 | HRH1 (0.98) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL16651410 | 0.99 | HRH1 (0.98) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL16652202 | 0.99 | HRH1 (0.98) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL1395674 | 0.99 | HRH1 (0.98) | HRH1KCNH2LMNADRD3HTR2A | |
| Fexofenadine SCHEMBL20531399 | 0.99 | HRH1 (0.98) | HRH1KCNH2LMNADRD3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 222 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4637708-A2 | SEMIFLUORINATED ALKANE COMPOSITIONS COMPRISING HYOSCYAMINE | Novaliq GmbH (DE) | 2025-10-29 | — | — | EP | claimed |
| WO-2024133913-A9 | SEMIFLUORINATED ALKANE COMPOSITIONS COMPRISING HYOSCYAMINE | NOVALIQ GMBH (DE) | 2025-03-20 | — | — | WO | claimed |
| WO-2024133913-A2 | SEMIFLUORINATED ALKANE COMPOSITIONS COMPRISING HYOSCYAMINE | NOVALIQ GMBH (DE) | 2024-06-27 | — | — | WO | claimed |
| EP-2173169-B1 | NASAL DELIVERY OF AQUEOUS CORTICOSTEROID SOLUTIONS | CYDEX PHARMACEUTICALS INC (US) | 2014-05-21 | — | — | EP | claimed |
| EP-2173169-A1 | NASAL AND OPHTHALMIC DELIVERY OF AQUEOUS CORTICOSTEROID SOLUTIONS | CyDex Pharmaceuticals, Inc. (US) | 2010-04-14 | — | — | EP | claimed |
| WO-2009003199-A1 | NASAL AND OPHTHALMIC DELIVERY OF AQUEOUS CORTICOSTEROID SOLUTIONS | CYDEX PHARMACEUTICALS, INC. (US) | 2008-12-31 | — | — | WO | claimed |
| EP-0997143-B1 | Soft chewable tablets | MCNEIL PPC INC (US) | 2007-12-19 | — | — | EP | claimed |
| EP-1214937-B1 | Terfenadine carboxylate and the treatment of dermal irritation | SEPRACOR INC (US) | 2007-05-30 | — | — | EP | claimed |
| US-20060205782-A1 | Method of providing an antihistaminic effect in a hepatically impaired patient | MERRELL PHARMACEUTICALS, INC. | 2006-09-14 | — | — | US | claimed |
| EP-1688142-A1 | Terfenadine carboxylate and the treatment of dermal irritation | Sepracor Inc. (US) | 2006-08-09 | — | — | EP | claimed |
| CN-1136775-A | Treatment of allergic disorders with terfenadine carboxylate | HOECHST MARIENRUS CO (US) | 1996-11-27 | — | — | CN | claimed |
| EP-0723446-A1 | TREATMENT OF ALLERGIC DISORDERS WITH TERFENADINE CARBOXYLATE | HOECHST MARION ROUSSEL, INC. (US) | 1996-07-31 | — | — | EP | claimed |
| EP-0701443-A1 | TERFENADINE METABOLITES AND THEIR OPTICALLY PURE ISOMERS FOR TREATING ALLERGIC DISORDERS | SEPRACOR, INC. (US) | 1996-03-20 | — | — | EP | claimed |
| US-5458879-A | Drug delivery | THE PROCTER & GAMBLE COMPANY (US) | 1995-10-17 | — | — | US | claimed |
| WO-1995023591-A1 | ORAL VEHICLE COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 1995-09-08 | — | — | WO | claimed |
| WO-1995010278-A1 | TREATMENT OF ALLERGIC DISORDERS WITH TERFENADINE CARBOXYLATE | HOECHST MARION ROUSSEL, INC. (US) | 1995-04-20 | — | — | WO | claimed |
| EP-0636365-A1 | Freeze-dried pharmaceutical dosage form and process for preparation thereof | McNEIL-PPC, INC. (US) | 1995-02-01 | — | — | EP | claimed |
| EP-0636364-A1 | Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof | McNEIL-PPC, INC. (US) | 1995-02-01 | — | — | EP | claimed |
| US-5375693-A | Methods and compositions for treating allergic disorders and other disorders metabolic derivatives of terfenadine | SEPRACOR, INC. (US) | 1994-12-27 | — | — | US | claimed |
| WO-1994003170-A1 | TERFENADINE METABOLITES AND THEIR OPTICALLY PURE ISOMERS FOR TREATING ALLERGIC DISORDERS | SEPRACOR INC. (US) | 1994-02-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205782-A1 | Method of providing an antihistaminic effect in a hepatically impaired patient | HRH3, HRH2, HRH1 | HRH1 3/4885KCNH2 1251/4885LMNA 3894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.